Meeting
2016 ASCO Annual Meeting
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer.
Authors
Glenn Liu
University of Wisconsin Carbone Cancer Center, Madison, WI
Glenn Liu , Lawrence Fong , Emmanuel S. Antonarakis , Jens C. Eickhoff , Laura E. Johnson , Douglas G. McNeel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01341652
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS3114)
DOI
10.1200/JCO.2016.34.15_suppl.TPS3114
Abstract #
TPS3114
Poster Bd #
426b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.
First Author: Glenn Liu
Poster
2020 Genitourinary Cancers Symposium
Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).
First Author: Hamid Emamekhoo
Poster
2020 ASCO Virtual Scientific Program
A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC).
First Author: Roisin Eilish O'Cearbhaill
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf